Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to -$2.9 million.

  • Myriad Genetics' Non Operating Income fell 14166.67% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.4 million, marking a year-over-year decrease of 45000.0%. This contributed to the annual value of $1.1 million for FY2024, which is 12291.67% up from last year.
  • According to the latest figures from Q3 2025, Myriad Genetics' Non Operating Income is -$2.9 million, which was down 14166.67% from -$1.4 million recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' Non Operating Income peaked at $120.6 million during Q3 2021, and registered a low of -$2.9 million during Q1 2021.
  • Its 5-year average for Non Operating Income is $7.5 million, with a median of -$700000.0 in 2024.
  • Its Non Operating Income has fluctuated over the past 5 years, first skyrocketed by 304146.34% in 2021, then tumbled by 250000.0% in 2023.
  • Myriad Genetics' Non Operating Income (Quarter) stood at $120.6 million in 2021, then crashed by 99.34% to $800000.0 in 2022, then plummeted by 212.5% to -$900000.0 in 2023, then soared by 133.33% to $300000.0 in 2024, then plummeted by 1066.67% to -$2.9 million in 2025.
  • Its Non Operating Income was -$2.9 million in Q3 2025, compared to -$1.4 million in Q2 2025 and -$400000.0 in Q1 2025.